Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Gains from Investment Securities (2022 - 2026)

Sagimet Biosciences' Gains from Investment Securities history spans 5 years, with the latest figure at $721081.0 for Q1 2026.

  • Quarterly Gains from Investment Securities rose 490431.29% to $721081.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $721081.0 through Mar 2026, up 490431.29% year-over-year, with the annual reading at $5.7 million for FY2025, 28.23% up from the prior year.
  • Gains from Investment Securities came in at $721081.0 for Q1 2026, up from -$48000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.3 million in Q3 2024 to a low of -$104000.0 in Q4 2023.
  • The 5-year median for Gains from Investment Securities is $19314.0 (2024), against an average of $927141.2.
  • Year-over-year, Gains from Investment Securities plummeted 300.0% in 2023 and then soared 490431.29% in 2026.
  • Sagimet Biosciences' Gains from Investment Securities stood at -$1000.0 in 2022, then plummeted by 10300.0% to -$104000.0 in 2023, then soared by 4256.12% to $4.3 million in 2024, then plummeted by 101.11% to -$48000.0 in 2025, then soared by 1602.25% to $721081.0 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Gains from Investment Securities are $721081.0 (Q1 2026), -$48000.0 (Q4 2025), and $1.3 million (Q3 2025).